Thrombin Receptor Agonist Peptide
(Synonyms: 凝血酶受体兴奋剂) 目录号 : GC10140
A peptide agonist of the α-thrombin receptor
Cas No.:137339-65-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sfllrnpndkyepf is a synthetic thrombin receptor agonist peptide.
Thrombin cleaves its receptor at arginine-41, resulting in the generation of a new receptor NH2-terminus with the sequence Sfllrnpndkyepf. This peptide (TRP-14) may signal a variety of thrombin's responses[1]. Sfllrnpndkyepf, representing the 14 amino acids starting with Ser-42 of the human thrombin receptor, was found to mimic the effect of thrombin on platelets. Cleavage of the human platelet thrombin receptor by thrombin exposes a new N-terminal which acts as a putative tethered ligand. Sfllrnpndkyepf, corresponding to the new N-terminal region, activates and induces platelet aggregation and serotonin secretion. Sfllrnpndkyepf is the minimal peptide length which retains full activity in inducing [14C]serotonin secretion[2]. TRAP induces rapid morphological changes in HUVECs, with marked increase in the release of prostacyclin, endothelin, platelet activating factor, tissue type plasminogen activator, and plasminogen activator inhibitor-1. Incubation of cells with TRAP also induces a rapid decrease in cell-surface thrombomodulin[3].
References:
[1]. Sugama Y, et al. Thrombin receptor 14-amino acid peptide mediates endothelial hyperadhesivity and neutrophil adhesion by P-selectin-dependent mechanism. Circ Res. 1992 Oct;71(4):1015-9.
[2]. Sabo T, et al. Structure-activity studies of the thrombin receptor activating peptide. Biochem Biophys Res Commun. 1992 Oct 30;188(2):604-10.
[3]. Maruyama Y, et al. Thrombin receptor agonist peptide decreases thrombomodulin activity in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1262-9.
| Cas No. | 137339-65-2 | SDF | |
| 别名 | 凝血酶受体兴奋剂 | ||
| Canonical SMILES | CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCC(=O)O)C(=O)N3CCCC3C(=O)NC(CC4=CC=CC=C4)C(=O)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CO)N | ||
| 分子式 | C81H118N20O23 | 分子量 | 1739 |
| 溶解度 | Soluble to 0.90 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.575 mL | 2.8752 mL | 5.7504 mL |
| 5 mM | 0.115 mL | 0.575 mL | 1.1501 mL |
| 10 mM | 0.0575 mL | 0.2875 mL | 0.575 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。